In Europe, three additional agents are available: lumiracoxib, etoricoxib, and parecoxib, the parenteral form of valdecoxib. Although traditional and COX-2-selective NSAIDs have commonly been used ...

Although there were no significant differences between etoricoxib and diclofenac for ... perspective on the effects of nsNSAIDs and COX-2 selective inhibitors on adjudicated CHF resulting in ...

Etoricoxib, a COX-2 inhibitor that's not approved in the United States, has four times the risk of cardiovascular death compared to a placebo. As you can see, COX-2 inhibitors can increase your ...